Autotelic Bio, which researches and develops new immuno-anticancer drugs and fixed dose combination new drugs, has successfully raised Series A funding worth KRW 6.5 billion, including KRW 3 billion by Mega Investment, KRW 2.5 billion by UTC Investment, and a total of KRW 1 billion from Aju Pharmaceutical and Korea Credit Guarantee Fund last October. 

The Series A Funding is expected to close in the upcoming February, and if considering an additional investment of KRW 1.5 billion, the amount of Series A can be expanded to KRW 8 billion. 

Autotelic Bio currently has three anti-cancer new drugs and four hybrid new drug pipelines. Considering the high risk of new drug development, the company has established a hybrid new drug pipeline that can launch products quickly while reducing development costs, focusing more on commercialization. It can be said to clearly show the business strategies of management team who previously worked in pharmaceutical companies.

Autotelic Bio is rapidly developing new and improved new drugs by building a pipeline with a high potential for commercialization based on a utility-centered development strategy. Depending on the capabilities of the management team with technology transfer know-how, the possibility of technology transfer through commercialization is also high.